Advanced search
Search:  

1 - 7 of 7 results found for `CETP inhibition`.

  1. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase...

    Cholesteryl ester transfer protein (CETP) inhibition reduces vascular event risk, but confusion surrounds its effects on low-density lipoprotein (LDL) cholesterol. Here, we clarify associations of genetic inhibition of CETP on detailed lipoprotein

    http://iris.ucl.ac.uk/iris/publication/1732738/1

  2. Lipoprotein Signatures of Cholesteryl Ester Transfer Protein and HMG-CoA Reductase...

    Background: CETP inhibition reduces vascular event rates but confusion surrounds its low-density lipoprotein (LDL)-cholesterol effects. We sought to clarify associations of genetic inhibition of CETP on detailed lipoproteins. Methods and Results: We

    http://iris.ucl.ac.uk/iris/publication/1570534/1

  3. Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease

    Drug development of cholesteryl ester transfer protein (CETP) inhibition to prevent coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and

    http://iris.ucl.ac.uk/iris/publication/1818974/18

  4. Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease

    Drug development of cholesteryl ester transfer protein (CETP) inhibition to prevent coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and

    http://iris.ucl.ac.uk/iris/publication/1816348/18

  5. Separating the mechanism-based and off-target actions of cholesteryl ester transfer...

    BACKGROUND: Cholesteryl ester transfer protein (CETP) inhibitors raise high-density lipoprotein (HDL) cholesterol, but torcetrapib, the first-in-class inhibitor tested in a large outcome trial, caused an unexpected blood pressure elevation and

    http://iris.ucl.ac.uk/iris/publication/347469/1

  6. Separating the mechanism-based and off-target actions of cholesteryl ester transfer...

    BACKGROUND: Cholesteryl ester transfer protein (CETP) inhibitors raise high-density lipoprotein (HDL) cholesterol, but torcetrapib, the first-in-class inhibitor tested in a large outcome trial, caused an unexpected blood pressure elevation and

    http://iris.ucl.ac.uk/iris/publication/125404/1

  7. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart...

    Aims: High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport protein (CETP)

    http://iris.ucl.ac.uk/iris/publication/406167/7

  8. Page: 1